Mod GRF (1-29) 5mg (CJC-1295 no DAC)
Modified GRF (CJC-1295 No DAC) is a truncated peptide analogue of growth hormone-releasing hormone (GHRH). Developed to enhance muscle repair, growth, wound healing, bone strength, fat burning, metabolism, and possibly blood sugar regulation and immune system function, this peptide has shown significant therapeutic potential.
Modified GRF (CJC-1295 No DAC) is a truncated peptide analogue of growth hormone-releasing hormone (GHRH). Developed to enhance muscle repair, growth, wound healing, bone strength, fat burning, metabolism, and possibly blood sugar regulation and immune system function, this peptide has shown significant therapeutic potential.
Modified GRF (CJC-1295 No DAC) is a truncated peptide analogue of growth hormone-releasing hormone (GHRH). Developed to enhance muscle repair, growth, wound healing, bone strength, fat burning, metabolism, and possibly blood sugar regulation and immune system function, this peptide has shown significant therapeutic potential.
Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabled as a drug, food or cosmetic.
What is Modified GRF (1-29)?
Modified GRF (1-29) is a peptide analogue of GHRH, first developed in the 1980s. Researchers discovered that the first 29 amino acids of GHRH retained all the properties of the full 44-amino-acid protein. This smaller fragment, known as GRF (1-29), effectively mirrors the activity of GHRH but has a very short half-life, limiting its therapeutic potential.
To address this, scientists further modified GRF (1-29) by substituting four amino acids to prevent degradation and oxidation, both during manufacture and transport as well as within the body. These modifications also increased its binding affinity to GHRH receptors. This enhanced version, known as Modified GRF (1-29), has a longer half-life and greater therapeutic potential. It is sometimes referred to as Mod GRF or tetrasubstituted GRF (1-29).
CJC-1295 No DAC vs. Modified GRF (1-29)
Modified GRF (1-29) is chemically identical to CJC-1295 No DAC. Both peptides consist of the first 29 amino acids of GHRH and include modifications to improve stability and effectiveness. These peptides are distinguished by their lack of the Drug Affinity Complex (DAC), which means they have a shorter half-life compared to CJC-1295 with DAC.
Key Differences
GRF (1-29): The original peptide with a very short half-life.
Modified GRF (1-29): Enhanced version with four substituted amino acids for better stability and receptor binding.
CJC-1295 No DAC: Identical to Modified GRF (1-29), lacking the Drug Affinity Complex.
Mod GRF (1-29) (CJC-1295 No DAC) Peptide Structure
Source: Oxford Academic
Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg
Molecular Formula: C152H252N44O42
Molecular Weight: 3367.954 g/mol
PubChem CID: 56841945
CAS Number: 863288-34-0
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.
